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Background
Bavituximab is a novel chimeric IgG1 monoclonal anti-
body targeting the membrane phospholipid, phosphati-
dylserine (PS), externalized on the luminal surface of
endothelium in tumors, tumor cells, and tumor exo-
somes under stressor conditions in the tumor microen-
vironment. PS exposure on tumor vessels is increased
by chemotherapy and irradiation, thereby amplifying the
target for bavituximab. The purpose of this investigation
was to develop OpalTM 6-plex quantitative immuno-
fluorescence (IF) assays ImmunoProfiling the tumor
microenvironment of rectal adenocarcinoma (seven),
hepatocellular carcinoma (HCC) (six), and advanced
melanoma (two) patients treated with bavituximab com-
bination treatments and to identify biomarkers that cor-
relate immune response to patient survival.
Methods
OpalTM 6-plex quantitative IF assays utilizing Vectra
Imaging System with inForm software were developed to
evaluate the presence of immune infiltrates in pre- and
post-treatment biopsies, or residual surgery specimen
obtained from consented patients in three investigator-
sponsored clinical trials with UTSW IRB approval. For-
malin fixed paraffin embedded samples of patients pri-
mary tumor and post treatment, or residual surgery
specimen were immuno stained with i) panel of lymphoid
cell markers for CD4, CD8, PD-1, FoxP3, GranzymeB,
IL-2 and DAPI, ii) panel of myeloid cell markers for
CD68, iNOS, Arg-1, CD31, CD33, CD14 and DAPI, iii)
panel of dendritic cell markers for PD-L1, CD11c, CD80,
CD86, HLA-DR, PS, and DAPI with same species fluores-
cence primary antibodies labeling without cross-reactivity
using tyramide signal amplification. These custom-
designed assays allow single cell coexpression of multiple
biomarkers in the same tissue section and can be used to
quantify specific immune cells infiltration and immuno-
modulation of the tumor microenvironment mediated by
bavituximab.
Results
Preliminary results demonstrate reliable detection, quan-
tification, and phenotyping of lymphocytes and mono-
cytes present in tumor tissues obtained from consented
rectal adenocarcinoma, HCC, and advanced melanoma
patients treated with bavituximab combination therapies.
Conclusions
OpalTM 6-plex quantitative IF assays present a unique cap-
ability and read out assay for elucidating immunomodula-
tion of macrophages and dendritic cells mediated by
bavituximab.
Written informed consent (ICF) was obtained from all
patients to collect biopsies for exploratory biomarkers
research and for publication of this abstract and any
accompanying images. A copy of the written consent is
available for review by the editor of this journal.
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